Clopidogrel Current Events

Clopidogrel Current Events, Clopidogrel News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 7 | 280 Results
Aspirin is most cost effective way to prevent heart disease
Aspirin and blood pressure lowering drugs can prevent heart disease at a fraction of the cost of cholesterol lowering drugs (statins) and clopidogrel (an anti-clotting drug), finds a study in this week's BMJ. (2003-11-27)

Many physicians still prescribe controversial drug combination
Safety concerns of the concomitant use of clopidogrel with the proton pump inhibitors (PPIs) omeprazole or esomeprazole were published in May 2009 and February 2010 by European regulatory agencies. After the last publication, there was an observed drop in dispensing these medicines in the Netherlands: 11.9 percent decreases for omeprazole and esomeprazole, versus an increase of 16.0 percent for other PPIs. Still 22.6 percent of patients started on omeprazole and esomeprazole in February 2010, placing them at risk for cardiovascular events. (2016-08-02)

Certain combined medications following heart attack may increase risk of death
Following an acute coronary syndrome such as a heart attack or unstable angina, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of the antiplatelet drug clopidogrel and aspirin have an increased risk of subsequent hospitalization for acute coronary syndrome or death, according to a study in the March 4 issue of JAMA. (2009-03-03)

McMaster study contradicts reports of problems with blood thinner
New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood thinner clopidogrel, also known as Plavix. (2010-08-29)

Combination anti-clotting therapy raises bleeding risk for people at high risk of recurrent stroke
The combination of two anti-clotting agents, aspirin and clopidogrel-- known to be beneficial for people with cardiovascular disease--should not be recommended treatment for patients who have cerebrovascular disease, conclude authors of a study in this week's issue of The Lancet. (2004-07-22)

Patients at risk of adverse events within 3 months after stopping certain ACS therapy
Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the Feb. 6 issue of JAMA. (2008-02-05)

Combination therapy reduces occurrence, number of migraines following cardiac procedure
Josep Rodes-Cabau, M.D., of Laval University, Quebec City, Canada, and colleagues randomly assigned 171 patients with an indication for atrial septal defect (ASD) closure and no history of migraine to receive dual antiplatelet therapy (aspirin + clopidogrel [the clopidogrel group], n = 84) or single antiplatelet therapy (aspirin + placebo [the placebo group], n = 87) for 3 months following transcatheter ASD closure. (2015-11-09)

Heart attack patients given more antithrombotic drugs have increased risk of hospital admission for bleeding
In heart attack patients, risk of hospital admission for bleeding increases with the number of antithrombotic drugs used. Patients with nonfatal bleeding are also much more likely to suffer repeat heart attack or die than those without this nonfatal bleeding. This analysis of more than 40,000 Danish patients is reported in an article in this week's edition of the Lancet. (2009-12-10)

Breakthrough in drug trial offers hope for heart attack patients
New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks. (2010-09-13)

Clopidogrel reduces death, stroke, heart attack now and later
The blood thinner clopidogrel, when used with aspirin, reduced the risk of subsequent heart attack, stroke and death in people who came to the emergency department with new or increasing chest pain or a heart attack, according to a report in today's rapid access issue of Circulation: Journal of the American Heart Association. (2003-02-17)

Results of the TRIGGER-PCI trial reported at TCT 2011
A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of cardiac death or myocardial infarction -- the primary endpoint -- at six month follow up. Results of the TRIGGER-PCI trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. (2011-11-09)

Desensitization protocol overcomes allergy to clopidogrel
A careful desensitization protocol can help patients overcome allergic reactions to anti-clotting medication critical to preventing new blockages inside coronary stents, according to a study being presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 29th Annual Scientific Sessions in Chicago, May 10-13. (2006-05-11)

Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions. (2011-11-16)

Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in the Canadian Medical Association Journal has found. (2009-01-28)

Warfarin remains gold-standard for preventing stroke in patients with heart abnormality
Despite their side effects, treatments like warfarin are still the best way to prevent stroke in patients with atrial fibrillation (an abnormal heart rhythm), according to a paper in this week's issue of The Lancet. (2006-06-08)

Jefferson scientists find that plavix appears to be safe during and after heart bypass
Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College. (2007-03-27)

Proton pump inhibitors do not interfere with benefit of antiplatelet drugs clopidogrel or prasugrel in patients after an acute coronary syndrome
Proton pump inhibitors do not interfere with the clinical benefit of the anti-clotting drugs clopidogrel or prasugrel in patients after an acute coronary syndrome. These findings are in contrast to other recent studies that have shown potential harm when these two classes of drugs are combined. The results are published in an article online first and in an upcoming edition of the Lancet. (2009-08-31)

Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
A study showing that diabetic patients who are treated with long-term anti-clotting therapy are less likely to have a heart attack or die more than a year after stenting has been named among the best research papers presented at the 30th annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions. (2007-05-17)

Some heart attack patients may be resistant to blood thinner
A substantial proportion of heart attack patients may be resistant to the blood thinner clopidogrel - and face an increased risk of recurrent blockages. (2004-06-07)

Results of the ELISA II trial
Aspirin and Clopidogrel are widely used and proven to be effective in the treatment of an acute coronary syndrome (ACS). (2005-09-06)

New evidence on co-prescribing for heart and stroke patients
New research by the University of East Anglia shows no risk in combining two commonly prescribed treatments for patients at risk of heart attacks and strokes. (2010-04-08)

High-dose anticlotting drug cuts heart attack, death risk in half
Pretreatment with double-dose anticlotting medication just before percutaneous coronary intervention cuts the combined risk of heart attack and cardiac death by half, according to a study reported at the 30th annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions, May 9-12, 2007, in Orlando, Fla. (2007-05-11)

Ticagrelor is better than clopidogrel to prevent blood clots regardless of genetic profile, thus eliminating need for genetic testing
A study published online first and in an upcoming Lancet shows that anti-clotting treatment using ticagrelor is better than clopidogrel, regardless of the presence of genetic variations that leads to variable efficacy of clopidogrel. Thus use of ticagrelor in patients with acute coronary syndromes eliminates the need for genetic testing that is considered necessary to avoid a poor response when treating with clopidogrel. (2010-08-29)

Genetic variation in young heart attack patients makes anti-clotting drug clopidogrel less effective
If a young heart attack patient (under 45 years of age) has a certain genetic variation, the anti-clotting drug clopidogrel is less effective in that person and they are much more likely to die, have another heart attack, require urgent repeat coronary intervention or have stent thrombosis. These are the conclusions of authors of an article published online first and in an upcoming edition of rhe Lancet, written by Dr. Gilles Montalescot, Hopital Pitie-Salpetriere, Paris, France, and colleagues. (2008-12-22)

Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective
The antiplatelet medicine clopidogrel is not only effective in reducing the risk of recurrent heart attack and stroke, it is also extremely cost-effective, according to data presented today by researchers from Emory University at the American Heart Association's Scientific Sessions. (2003-11-12)

New drug could substantially reduce deaths from heart attack
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives each year, according to a study published in this week's issue of The Lancet. The treatment should be considered routinely for suspected heart attacks, state the authors, as it can safely reduce mortality in hospital for a wide range of patients. (2005-11-03)

Administration of clopidogrel prior to PCI associated with reduction in major cardiac events
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events. (2012-12-18)

Some heart attack patients may be resistant to blood thinner
A substantial proportion of heart attack patients may be resistant to the blood thinner clopidogrel - and face an increased risk of recurrent blockages, researchers report in today's rapid access issue of Circulation: Journal of the American Heart Association. (2004-06-08)

Part of drug trial for patients with atrial fibrillation discontinued
Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin). (2005-09-06)

Researcher recommends stronger antithrombotic drugs in high-risk heart attack patients
The Cardiovascular Research Laboratory of the IDIBELL led by the cardiologist of the Bellvitge University Hospital José Luis Ferreiro has conducted a study on the effect of anti-platelet drugs given to high risk patients suffering from acute myocardial infarction (heart attack) in the context of the Infarction Code. (2013-06-06)

Global platelet reactivity and high risk ACS patients
Global platelet reactivity identifies high risk ACS patients more effectively than responsiveness to clopidogrel. (2012-08-28)

Acute coronary syndromes -- Did prasugrel & ticagrelor offer same benefits as clopidogrel?
In patients presenting with acute coronary syndromes (ACS) either with or without ST-segment elevation MI (STEMI and NSTEMI), dual antiplatelet therapy (DAPT) is recommended for at least 1 year independently of whether revascularization is performed. (2018-02-07)

Study examines outcomes of high-dose antiplatelet drug after stent placement
Modifying a patient's dosage of the antiplatelet drug clopidogrel for 6 months depending on the patient's level of platelet reactivity did not result in combined lower rates of nonfatal heart attack, stent thrombosis (clot) and cardiovascular death in patients who had a procedure such as balloon angioplasty and received a drug-releasing coronary stent, according to a study in the March 16 issue of JAMA. (2011-03-15)

Double doses of clopidogrel better than standard doses for heart patients undergoing angioplasty
A landmark international study led by McMaster University researchers found high doses of the blood thinner clopidogrel significantly reduce complications in heart patients undergoing angioplasty to clear blocked arteries. (2009-08-30)

Antiplatelets: 1 person, 1 dose?
An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the (2011-04-14)

Clot-preventing drug can cause potentially fatal blood disorder
Northwestern University researchers Charles L. Bennett, M.D., and Charles J. Davidson, M.D., report that clopidogrel, a new blood clot-preventing drug taken by one million patients, can cause a rare but potentially fatal blood disease known as thrombotic thrombocytopenic purpura. The disorder almost always appears within two weeks of starting clopidogrel therapy. (2000-04-19)

Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel
Patients with a certain genetic variation who received the anti-platelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the Aug. 26 issue of JAMA. (2009-08-25)

ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome
Patients who suffer from acute ischemia of the heart muscle benefit if they use clopidogrel in addition to acetylsalicylic acid (ASA) as early as possible. Their risk of suffering a heart attack is reduced measurably. This is the conclusion of a report by the German Institute for Quality and Efficiency in Health Care, Cologne, which was published in March 2009 and for which an English-language summary is now available. (2009-04-21)

Study shows benefits of anti-clotting medications reduced by common heartburn drugs
The anti-clotting action of the medication clopidogrel can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50 percent increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions 32nd Annual Scientific Sessions. (2009-05-06)

Personalized antiplatelet treatment improves outcome after PCI
Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012. (2012-08-28)

Page 1 of 7 | 280 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.